Listed

Nuvectis Pharma, Inc.

NVCTNasdaqCIK 1875558HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$7.2m, Q2 FY2026
Net income−$7.0m, Q2 FY2026
Nuvectis Pharma, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$k4,486Research and development, Q3 FY2023, three months to 2023-09-30$4.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure4,265Research and development, Q4 FY2023, three months to 2023-12-31$4.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-25, accession 0001558370-25-001496. Derived: 12-month figure less the 9-month figure.Report this figure2,660Research and development, Q1 FY2024, three months to 2024-03-31$2.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure2,943Research and development, Q2 FY2024, three months to 2024-06-30$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure2,819Research and development, Q3 FY2024, three months to 2024-09-30$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure4,496Research and development, Q4 FY2024, three months to 2024-12-31$4.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-11, accession 0001104659-26-013044. Derived: 12-month figure less the 9-month figure.Report this figure3,680Research and development, Q1 FY2025, three months to 2025-03-31$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure3,613Research and development, Q2 FY2025, three months to 2025-06-30$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure5,774Research and development, Q3 FY2025, three months to 2025-09-30$5.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure5,086Research and development, Q4 FY2025, three months to 2025-12-31$5.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-11, accession 0001104659-26-013044. Derived: 12-month figure less the 9-month figure.Report this figure4,106Research and development, Q1 FY2026, three months to 2026-03-31$4.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure4,684Research and development, Q2 FY2026, three months to 2026-06-30$4.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Operating income$k(6,158)Operating income, Q3 FY2023, three months to 2023-09-30−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure(6,866)Operating income, Q4 FY2023, three months to 2023-12-31−$6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-25, accession 0001558370-25-001496. Derived: 12-month figure less the 9-month figure.Report this figure(4,396)Operating income, Q1 FY2024, three months to 2024-03-31−$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure(4,643)Operating income, Q2 FY2024, three months to 2024-06-30−$4.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure(4,359)Operating income, Q3 FY2024, three months to 2024-09-30−$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure(6,449)Operating income, Q4 FY2024, three months to 2024-12-31−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-11, accession 0001104659-26-013044. Derived: 12-month figure less the 9-month figure.Report this figure(5,568)Operating income, Q1 FY2025, three months to 2025-03-31−$5.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure(6,595)Operating income, Q2 FY2025, three months to 2025-06-30−$6.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure(7,794)Operating income, Q3 FY2025, three months to 2025-09-30−$7.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure(7,617)Operating income, Q4 FY2025, three months to 2025-12-31−$7.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-11, accession 0001104659-26-013044. Derived: 12-month figure less the 9-month figure.Report this figure(6,260)Operating income, Q1 FY2026, three months to 2026-03-31−$6.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure(7,197)Operating income, Q2 FY2026, three months to 2026-06-30−$7.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Net income$k(5,881)Net income, Q3 FY2023, three months to 2023-09-30−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure(6,622)Net income, Q4 FY2023, three months to 2023-12-31−$6.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-25, accession 0001558370-25-001496. Derived: 12-month figure less the 9-month figure.Report this figure(4,171)Net income, Q1 FY2024, three months to 2024-03-31−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure(4,428)Net income, Q2 FY2024, three months to 2024-06-30−$4.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure(4,153)Net income, Q3 FY2024, three months to 2024-09-30−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure(6,248)Net income, Q4 FY2024, three months to 2024-12-31−$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0001104659-26-013044. Derived: 12-month figure less the 9-month figure.Report this figure(5,332)Net income, Q1 FY2025, three months to 2025-03-31−$5.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure(6,334)Net income, Q2 FY2025, three months to 2025-06-30−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure(7,462)Net income, Q3 FY2025, three months to 2025-09-30−$7.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure(7,314)Net income, Q4 FY2025, three months to 2025-12-31−$7.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0001104659-26-013044. Derived: 12-month figure less the 9-month figure.Report this figure(6,050)Net income, Q1 FY2026, three months to 2026-03-31−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure(7,020)Net income, Q2 FY2026, three months to 2026-06-30−$7.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Diluted EPS$ per share(0.37)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figurenot reported(0.25)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure(0.26)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure(0.24)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figurenot reported(0.27)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure(0.30)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure(0.44)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figurenot reported(0.26)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure(0.30)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Basic EPS$ per share(0.37)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figurenot reported(0.25)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure(0.26)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure(0.24)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figurenot reported(0.27)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure(0.30)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure(0.44)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figurenot reported(0.26)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure(0.30)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure

Balance sheet

Cash and equivalents$22.2m, Q2 FY2026
Shareholders' equity$9.1m, Q2 FY2026
Nuvectis Pharma, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m22.1Cash and equivalents, Q3 FY2023, at 2023-09-30$22.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-08, accession 0001558370-23-018124.Report this figure19.1Cash and equivalents, FY2023, at 2023-12-31$19.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-25, accession 0001558370-25-001496.Report this figure19.5Cash and equivalents, Q1 FY2024, at 2024-03-31$19.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0001558370-24-007072.Report this figure18.1Cash and equivalents, Q2 FY2024, at 2024-06-30$18.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0001558370-24-010971.Report this figure17.2Cash and equivalents, Q3 FY2024, at 2024-09-30$17.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure18.5Cash and equivalents, FY2024, at 2024-12-31$18.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-11, accession 0001104659-26-013044.Report this figure29.9Cash and equivalents, Q1 FY2025, at 2025-03-31$29.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure26.8Cash and equivalents, Q2 FY2025, at 2025-06-30$26.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure35.4Cash and equivalents, Q3 FY2025, at 2025-09-30$35.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure31.6Cash and equivalents, FY2025, at 2025-12-31$31.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure25.1Cash and equivalents, Q1 FY2026, at 2026-03-31$25.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure22.2Cash and equivalents, Q2 FY2026, at 2026-06-30$22.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Current assets$m22.3Current assets, Q3 FY2023, at 2023-09-30$22.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-08, accession 0001558370-23-018124.Report this figure19.2Current assets, FY2023, at 2023-12-31$19.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-25, accession 0001558370-25-001496.Report this figure19.7Current assets, Q1 FY2024, at 2024-03-31$19.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007072.Report this figure18.3Current assets, Q2 FY2024, at 2024-06-30$18.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0001558370-24-010971.Report this figure17.3Current assets, Q3 FY2024, at 2024-09-30$17.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure18.6Current assets, FY2024, at 2024-12-31$18.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-11, accession 0001104659-26-013044.Report this figure30.1Current assets, Q1 FY2025, at 2025-03-31$30.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure27.0Current assets, Q2 FY2025, at 2025-06-30$27.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure35.6Current assets, Q3 FY2025, at 2025-09-30$35.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure31.7Current assets, FY2025, at 2025-12-31$31.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure25.4Current assets, Q1 FY2026, at 2026-03-31$25.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure22.4Current assets, Q2 FY2026, at 2026-06-30$22.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Total assets$m22.3Total assets, Q3 FY2023, at 2023-09-30$22.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-08, accession 0001558370-23-018124.Report this figure19.2Total assets, FY2023, at 2023-12-31$19.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-25, accession 0001558370-25-001496.Report this figure19.7Total assets, Q1 FY2024, at 2024-03-31$19.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001558370-24-007072.Report this figure18.3Total assets, Q2 FY2024, at 2024-06-30$18.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0001558370-24-010971.Report this figure17.3Total assets, Q3 FY2024, at 2024-09-30$17.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure18.6Total assets, FY2024, at 2024-12-31$18.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-11, accession 0001104659-26-013044.Report this figure30.1Total assets, Q1 FY2025, at 2025-03-31$30.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure27.0Total assets, Q2 FY2025, at 2025-06-30$27.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure35.6Total assets, Q3 FY2025, at 2025-09-30$35.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure31.7Total assets, FY2025, at 2025-12-31$31.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure25.4Total assets, Q1 FY2026, at 2026-03-31$25.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure22.4Total assets, Q2 FY2026, at 2026-06-30$22.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Current liabilities$m5.6Current liabilities, Q3 FY2023, at 2023-09-30$5.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-08, accession 0001558370-23-018124.Report this figure7.0Current liabilities, FY2023, at 2023-12-31$7.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-25, accession 0001558370-25-001496.Report this figure5.7Current liabilities, Q1 FY2024, at 2024-03-31$5.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007072.Report this figure5.8Current liabilities, Q2 FY2024, at 2024-06-30$5.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0001558370-24-010971.Report this figure6.3Current liabilities, Q3 FY2024, at 2024-09-30$6.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure8.9Current liabilities, FY2024, at 2024-12-31$8.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-11, accession 0001104659-26-013044.Report this figure9.2Current liabilities, Q1 FY2025, at 2025-03-31$9.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure10.1Current liabilities, Q2 FY2025, at 2025-06-30$10.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure11.6Current liabilities, Q3 FY2025, at 2025-09-30$11.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure13.3Current liabilities, FY2025, at 2025-12-31$13.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure11.2Current liabilities, Q1 FY2026, at 2026-03-31$11.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure13.3Current liabilities, Q2 FY2026, at 2026-06-30$13.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Total liabilities$m5.6Total liabilities, Q3 FY2023, at 2023-09-30$5.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-08, accession 0001558370-23-018124.Report this figure7.0Total liabilities, FY2023, at 2023-12-31$7.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-25, accession 0001558370-25-001496.Report this figure5.7Total liabilities, Q1 FY2024, at 2024-03-31$5.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001558370-24-007072.Report this figure5.8Total liabilities, Q2 FY2024, at 2024-06-30$5.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0001558370-24-010971.Report this figure6.3Total liabilities, Q3 FY2024, at 2024-09-30$6.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure8.9Total liabilities, FY2024, at 2024-12-31$8.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-11, accession 0001104659-26-013044.Report this figure9.2Total liabilities, Q1 FY2025, at 2025-03-31$9.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure10.1Total liabilities, Q2 FY2025, at 2025-06-30$10.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure11.6Total liabilities, Q3 FY2025, at 2025-09-30$11.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure13.3Total liabilities, FY2025, at 2025-12-31$13.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure11.2Total liabilities, Q1 FY2026, at 2026-03-31$11.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure13.3Total liabilities, Q2 FY2026, at 2026-06-30$13.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure
Shareholders' equity$m16.7Shareholders' equity, Q3 FY2023, at 2023-09-30$16.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure12.2Shareholders' equity, FY2023, at 2023-12-31$12.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-11, accession 0001104659-26-013044.Report this figure14.0Shareholders' equity, Q1 FY2024, at 2024-03-31$14.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure12.5Shareholders' equity, Q2 FY2024, at 2024-06-30$12.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure11.0Shareholders' equity, Q3 FY2024, at 2024-09-30$11.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure9.7Shareholders' equity, FY2024, at 2024-12-31$9.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure21.0Shareholders' equity, Q1 FY2025, at 2025-03-31$21.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure16.9Shareholders' equity, Q2 FY2025, at 2025-06-30$16.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure24.0Shareholders' equity, Q3 FY2025, at 2025-09-30$24.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure18.4Shareholders' equity, FY2025, at 2025-12-31$18.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure14.2Shareholders' equity, Q1 FY2026, at 2026-03-31$14.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure9.1Shareholders' equity, Q2 FY2026, at 2026-06-30$9.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure

Cash flow

Operating cash flow−$4.5m, Q2 FY2026
Nuvectis Pharma, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(3,244)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-05, accession 0001558370-24-014340. Derived: 9-month figure less the 6-month figure.Report this figure(3,850)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-25, accession 0001558370-25-001496. Derived: 12-month figure less the 9-month figure.Report this figure(4,358)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure(3,020)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0001558370-25-010203. Derived: 6-month figure less the 3-month figure.Report this figure(2,404)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001104659-25-105939. Derived: 9-month figure less the 6-month figure.Report this figure(2,465)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0001104659-26-013044. Derived: 12-month figure less the 9-month figure.Report this figure(4,174)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure(3,367)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001104659-26-090109. Derived: 6-month figure less the 3-month figure.Report this figure(4,494)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001104659-25-105939. Derived: 9-month figure less the 6-month figure.Report this figure(3,974)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0001104659-26-013044. Derived: 12-month figure less the 9-month figure.Report this figure(6,511)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$6.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure(4,531)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$4.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001104659-26-090109. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)23.48m, Q2 FY2026
Nuvectis Pharma, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares14.1Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3014,050,271 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-08, accession 0001558370-23-018124.Report this figure14.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3114,724,249 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001558370-24-007072.Report this figure15.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3015,178,035 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0001558370-24-010971.Report this figure16.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3016,104,446 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-05, accession 0001558370-24-014340.Report this figure16.6Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3116,559,335 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0001558370-25-006497.Report this figure16.9Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3016,900,570 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0001558370-25-010203.Report this figure17.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3017,230,559 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure19.9Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3119,937,507 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure21.4Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3021,366,268 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure22.7Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3022,719,057 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001104659-25-105939.Report this figure23.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3123,414,475 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001104659-26-055318.Report this figure23.5Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3023,475,989 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure

Shares outstanding: 32.58mShares outstanding, period not labelled, at 2026-07-3132,581,533 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-04, accession 0001104659-26-090109.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.